Avalo Therapeutics (AVTX) Short Interest Ratio & Short Volume → Breaking News: Elon Musk Invents New Type of A.I. (Shocking) (From InvestorPlace) (Ad) Free AVTX Stock Alerts $9.59 -0.05 (-0.52%) (As of 05/17/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Avalo Therapeutics Short Interest DataCurrent Short Volume104,300 sharesPrevious Short Volume153,400 sharesChange Vs. Previous Month-32.01%Dollar Volume Sold Short$1.79 millionShort Interest Ratio / Days to Cover0.2Last Record DateApril 30, 2024Outstanding Shares1,030,000 sharesPercentage of Shares Shorted10.13%Today's Trading Volume64,464 sharesAverage Trading Volume66,486 sharesToday's Volume Vs. Average97% Short Selling Avalo Therapeutics ? Sign up to receive the latest short interest report for Avalo Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatAVTX Short Interest Over TimeAVTX Days to Cover Over TimeAVTX Percentage of Float Shorted Over Time Ad The Freeport SocietyBiden Nomination CANCELED?The Hill just published that Joe Biden has received enough delegates to…“clinch the Democratic presidential nomination and all but guaranteeing he will face off against former President Trump again in November.” Why is he all BUT guaranteed the Democratic nomination, in their words?I believe I have the terrifying answer right here. Avalo Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/2024104,300 shares $1.79 million -32.0%N/A0.2 $17.12 4/15/2024153,400 shares $2.34 million +95.4%N/A0.2 $15.24 3/31/202478,500 shares $1.71 million +16.8%N/A0.1 $21.75 3/15/202467,200 shares $293,664.00 +10.3%N/A1.3 $4.37 2/29/202460,900 shares $268,569.00 -4.8%N/A0.7 $4.41 2/15/202464,000 shares $304,640.00 -21.3%N/A0.7 $4.76 Get the Latest News and Ratings for AVTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Avalo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/31/202481,300 shares $378,045.00 -4.0%N/A0.8 $4.65 1/15/202484,700 shares $484,484.00 +32.1%N/A0.7 $5.72 12/31/202364,100 shares $583,310.00 -99.5%N/A0.4 $9.10 12/15/202312,640,000 shares $758,400.00 +23.8%N/A0.2 $0.06 11/30/202310,210,000 shares $713,679.00 -43.7%N/A0.1 $0.07 11/15/202318,140,000 shares $1.79 million +40.8%N/A0.2 $0.10 10/31/202312,880,000 shares $1.41 million +3.5%N/A0.2 $0.11 10/15/202312,450,000 shares $1.85 million -29.1%N/A0.2 $0.15 9/30/202317,550,000 shares $2.12 million +471.7%90.2%0.3 $0.12 9/15/20233,070,000 shares $406,775.00 +220.1%15.8%0.1 $0.13 8/31/2023959,000 shares $95,900.00 +0.2%5.2%0.1 $0.10 8/15/2023957,300 shares $134,022.00 -10.5%5.2%0.2 $0.14 7/31/20231,070,000 shares $214,000.00 +20.6%5.8%0.6 $0.20 7/15/2023887,000 shares $294,572.70 +41.2%7.4%0.7 $0.33 6/30/2023628,400 shares $223,207.68 +1,528.0%5.3%0.6 $0.36 6/15/202338,600 shares $145,329.00 -9.4%0.4%0.1 $3.77 5/31/202342,600 shares $122,262.00 -2.7%0.4%0.6 $2.87 5/15/202343,800 shares $120,450.00 +17.1%0.4%0.9 $2.75 4/30/202337,400 shares $108,834.00 -23.8%0.3%1.2 $2.91 4/15/202349,100 shares $127,660.00 +172.8%0.4%1.7 $2.60 3/31/202318,000 shares $31,500.00 -3.7%0.2%0.7 $1.75 3/15/202318,700 shares $46,843.50 -24.6%0.2%1.1 $2.51 2/28/202324,800 shares $62,496.00 +30.5%0.4%1.6 $2.52 2/15/202319,000 shares $56,240.00 -32.4%0.3%1.3 $2.96 1/31/202328,100 shares $110,714.00 -30.8%0.3%1.7 $3.94 1/15/202340,600 shares $197,316.00 +17.0%0.5%2.7 $4.86 12/30/202234,700 shares $174,891.47 -15.0%0.4%2.4 $5.04 12/15/202240,800 shares $237,864.00 +9.4%0.5%3 $5.83 11/30/202237,300 shares $204,031.00 +9.1%0.4%2.3 $5.47 11/15/202234,200 shares $198,360.00 -3.1%0.4%1.7 $5.80 10/31/202235,300 shares $211,800.00 -27.5%0.4%1.1 $6.00 10/15/202248,700 shares $258,110.00 +10.9%0.6%1.4 $5.30 9/30/202243,900 shares $145,748.00 -34.1%0.5%1.2 $3.32 9/15/202266,600 shares $279,054.00 +26.1%0.8%1.3 $4.19Shocking $16T Elon Musk Crypto Leak (Ad)Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. AVTX Short Interest - Frequently Asked Questions What is Avalo Therapeutics' current short interest? Short interest is the volume of Avalo Therapeutics shares that have been sold short but have not yet been closed out or covered. As of April 30th, investors have sold 104,300 shares of AVTX short. Learn More on Avalo Therapeutics' current short interest. Which institutional investors are shorting Avalo Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Avalo Therapeutics: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Avalo Therapeutics' short interest increasing or decreasing? Avalo Therapeutics saw a decrease in short interest in the month of April. As of April 30th, there was short interest totaling 104,300 shares, a decrease of 32.0% from the previous total of 153,400 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Avalo Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to Avalo Therapeutics: MIRA Pharmaceuticals, Inc. (0.42%), Moleculin Biotech, Inc. (1.45%), Elevai Labs, Inc. (0.44%), Guardion Health Sciences, Inc. (14.33%), ABVC BioPharma, Inc. (7.35%), Monopar Therapeutics Inc. (1.24%), Akari Therapeutics, Plc (0.03%), Aeterna Zentaris Inc. (0.34%), Addex Therapeutics Ltd (1.85%), NuCana plc (1.21%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Avalo Therapeutics stock? Short selling AVTX is an investing strategy that aims to generate trading profit from Avalo Therapeutics as its price is falling. AVTX shares are trading down $0.05 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Avalo Therapeutics? A short squeeze for Avalo Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of AVTX, which in turn drives the price of the stock up even further. How often is Avalo Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including AVTX, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: MIRA Pharmaceuticals Short Squeeze Moleculin Biotech Short Squeeze Elevai Labs Short Squeeze Guardion Health Sciences Short Squeeze ABVC BioPharma Short Squeeze Monopar Therapeutics Short Squeeze Akari Therapeutics Short Squeeze Aeterna Zentaris Short Squeeze Addex Therapeutics Short Squeeze NuCana Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:AVTX) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaBiden Nomination CANCELED?The Freeport SocietyMissed NVDA? Buy this AI stock NOWChaikin AnalyticsUrgent Nvidia WarningAltimetryCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMost important medical advance in 100 yearsThe Oxford ClubCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceProtect Your Bank Account Before It’s Too LateWeiss Ratings